{"id":"aluminium-chloride","rwe":[{"pmid":"41901430","year":"2026","title":"Spectrophotometric Estimation of Polyphenolic Compounds in Willowherbs (Epilobium angustifolium L. and E. hirsutum L.) and Implications for Genetic Resource Conservation.","finding":"","journal":"Plants (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41883085","year":"2026","title":"Morinda lucida Leaf Metabolites Ameliorate Aluminium Chloride-Mediated Chronic Inflammation and Modulate Proteins-Linked to Erectile Dysfunction in Rat Testes.","finding":"","journal":"Chemistry & biodiversity","studyType":"Clinical Study"},{"pmid":"41808725","year":"2026","title":"Neuroprotective potential of silver nanoparticles synthesized using Sargassum polycystum in a Zebrafish model of Alzheimer's disease.","finding":"","journal":"3 Biotech","studyType":"Clinical Study"},{"pmid":"41732170","year":"2026","title":"Neuroprotective properties of Linzia gerberiformis aqueous leaves extract against aluminium chloride (AlCl(3)) -induced cognitive impairment: Involvement of cholinergic, GABAergic, and antioxidant mechanisms.","finding":"","journal":"IBRO neuroscience reports","studyType":"Clinical Study"},{"pmid":"41651776","year":"2026","title":"Phytochemical Screening and Antioxidant Capacity of Chloroxylon swietenia DC. Leaf Extracts.","finding":"","journal":"Biomedical chromatography : BMC","studyType":"Clinical Study"}],"_fda":{"id":"b725dd26-c793-51a4-e053-2a95a90a573d","set_id":"9fdcce3e-e4d4-41ae-8609-37987c12414e","openfda":{"unii":["3CYT62D3GA"],"route":["TOPICAL"],"rxcui":["244613","486109"],"spl_id":["b725dd26-c793-51a4-e053-2a95a90a573d"],"brand_name":["lumicain"],"spl_set_id":["9fdcce3e-e4d4-41ae-8609-37987c12414e"],"package_ndc":["10733-412-60"],"product_ndc":["10733-412"],"generic_name":["ALUMINIUM CHLORIDE HEXAHYDRATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["ALUMINUM CHLORIDE"],"manufacturer_name":["Medical Products Laboratories, Inc."],"is_original_packager":[true]},"version":"4","effective_time":"20201223","warnings_and_cautions":["CAUTION: Federal Law restricts sale and use to physician or licensed practitioner."],"dosage_and_administration":["FOR TOPICAL APPLICATION ONLY For Granulation Tissue Growth: Allow packing saturated in Lumicain to remain in nail groove for 48 hours; repeat if necessary. If hemmorrhage is profuse, dress wound with gauze saturated with Lumicain and allow to remain for 24 hours or longer."],"spl_product_data_elements":["lumicain Aluminium Chloride Hexahydrate WATER ALUMINUM CHLORIDE ALUMINUM CATION"],"package_label_principal_display_panel":["premier lumicain TM Topical Hemostatic Solution 60cc For Rapid Control of Minor Hemorrhage Each Gram Contains: Aluminium Chloride............250 mg. In an aqueous base. Enter section text here lbl"]},"tags":[{"label":"aluminium chloride","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"D10AX01","category":"atc"},{"label":"Topical","category":"route"},{"label":"Dental","category":"route"},{"label":"Cloth","category":"form"},{"label":"Cream","category":"form"},{"label":"Gel","category":"form"},{"label":"Liquid","category":"form"},{"label":"Active","category":"status"},{"label":"Hyperhidrosis","category":"indication"},{"label":"Antiperspirants","category":"pharmacology"},{"label":"Cosmetics","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"SWELLING FACE","source":"FDA FAERS","actionTaken":"5 reports"},{"date":"","signal":"LIP SWELLING","source":"FDA FAERS","actionTaken":"3 reports"},{"date":"","signal":"GLOMERULAR FILTRATION RATE DECREASED","source":"FDA FAERS","actionTaken":"2 reports"},{"date":"","signal":"REACTION TO DRUG EXCIPIENTS","source":"FDA FAERS","actionTaken":"2 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"2 reports"},{"date":"","signal":"ABDOMINAL PAIN","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"ABDOMINAL PAIN UPPER","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"COMA","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"HERPES ZOSTER","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"MALAISE","source":"FDA FAERS","actionTaken":"1 reports"}],"drugInteractions":[{"url":"/drug/levothyroxine-sodium","drug":"levothyroxine sodium","action":"Monitor closely","effect":"May interact with Aluminum Chloride, Levothyroxine Sodium","source":"DrugCentral","drugSlug":"levothyroxine-sodium"},{"url":"/drug/moxifloxacin","drug":"moxifloxacin","action":"Monitor closely","effect":"May interact with Aluminum Chloride, Moxifloxacin","source":"DrugCentral","drugSlug":"moxifloxacin"}],"commonSideEffects":[],"contraindications":["Eruption","Inflammatory dermatosis"]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=aluminium chloride","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:01:21.168689+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Aluminium Chloride","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:01:29.055721+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:01:26.770113+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=aluminium chloride","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:01:27.559106+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:01:18.400189+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:01:18.400203+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:01:29.488744+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4594252/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:01:28.703727+00:00"}},"allNames":"aluminum chloride","offLabel":[],"synonyms":["aluminium chloride","aluminum chloride"],"timeline":[],"brandName":"Aluminum Chloride","ecosystem":[{"indication":"Hyperhidrosis","otherDrugs":[{"name":"aluminium chlorohydrate","slug":"aluminium-chlorohydrate","company":""}],"globalPrevalence":null}],"mechanism":{"novelty":"First-in-class","modality":"Small Molecule","drugClass":"aluminium chloride","explanation":"","oneSentence":"","technicalDetail":"Aluminum chloride acts as a topical astringent, causing vasoconstriction and reducing sweat gland activity through a mechanism that is not fully understood, but is thought to involve the formation of a gel-like substance that physically blocks the sweat glands."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Aluminium_chloride","title":"Aluminium chloride","extract":"Aluminium chloride, also known as aluminium trichloride, is an inorganic compound with the formula AlCl3. It forms a hexahydrate with the formula [Al(H2O)6]Cl3, containing six water molecules of hydration. Both the anhydrous form and the hexahydrate are colourless crystals, but samples are often contaminated with iron(III) chloride, giving them a yellow colour.","wiki_history":"==History==\nAluminium chlorides were known in the 18th century as muriate of alumina, marine alum, argillaceous marine salt, muriated clay. It was first chemically studied in the 1830s."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4436","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=aluminium%20chloride","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=aluminium chloride","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Aluminium_chloride","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T08:39:14.704684","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:01:30.389811+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"resorcinol","drugSlug":"resorcinol","fdaApproval":"","relationship":"same-class"},{"drugName":"azelaic acid","drugSlug":"azelaic-acid","fdaApproval":"1995-09-13","patentExpiry":"Sep 18, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"dapsone","drugSlug":"dapsone","fdaApproval":"1979-07-03","patentExpiry":"Nov 18, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"clascoterone","drugSlug":"clascoterone","fdaApproval":"2020-08-26","patentExpiry":"Nov 20, 2028","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"aluminium chloride","indications":{"approved":[{"name":"Hyperhidrosis","source":"DrugCentral","snomedId":312230002,"regulator":"FDA","eligibility":"Adults and pediatric patients 9 years of age and older"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"resorcinol","brandName":"resorcinol","genericName":"resorcinol","approvalYear":"","relationship":"same-class"},{"drugId":"azelaic-acid","brandName":"azelaic acid","genericName":"azelaic acid","approvalYear":"1995","relationship":"same-class"},{"drugId":"dapsone","brandName":"dapsone","genericName":"dapsone","approvalYear":"1979","relationship":"same-class"},{"drugId":"clascoterone","brandName":"clascoterone","genericName":"clascoterone","approvalYear":"2020","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06745921","phase":"PHASE1","title":"Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-02-24","conditions":["West Nile Viral Infection"],"enrollment":30,"completionDate":"2027-11-01"},{"nctId":"NCT07221162","phase":"PHASE1","title":"A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-12-05","conditions":["COVID-19"],"enrollment":140,"completionDate":"2026-11-24"},{"nctId":"NCT07216430","phase":"PHASE2","title":"Safety and Efficacy of wSp Vaccine in Young Children","status":"RECRUITING","sponsor":"Serum Life Science Europe GmbH","startDate":"2025-09-29","conditions":["Acute Otitis Media (AOM)"],"enrollment":320,"completionDate":"2029-06"},{"nctId":"NCT07451561","phase":"NA","title":"Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals.","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2026-03","conditions":["Acute Aluminum Phosphide Poisoned Cases"],"enrollment":74,"completionDate":"2027-03"},{"nctId":"NCT06680479","phase":"PHASE1","title":"Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy","status":"SUSPENDED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-04-01","conditions":["HIV-1"],"enrollment":30,"completionDate":"2028-04-14"},{"nctId":"NCT06748404","phase":"PHASE2","title":"TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2025-01-31","conditions":["Immunotherapy-related Pruritus"],"enrollment":28,"completionDate":"2028-12"},{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":["COVID -19","SARS CoV 2 Infection"],"enrollment":1919,"completionDate":"2024-06-27"},{"nctId":"NCT07401277","phase":"PHASE1","title":"Actinic Keratoses Treated With 5-fluorouracil Plus Aluminum","status":"NOT_YET_RECRUITING","sponsor":"West Virginia University","startDate":"2026-03","conditions":["Actinic Keratoses"],"enrollment":32,"completionDate":"2027-08"},{"nctId":"NCT05092386","phase":"PHASE1","title":"Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2023-01-03","conditions":["Pneumococcal Infections"],"enrollment":310,"completionDate":"2024-05-28"},{"nctId":"NCT06305182","phase":"PHASE2","title":"Metreleptin in Anorexia Nervosa","status":"RECRUITING","sponsor":"Gabriella Milos","startDate":"2024-05-31","conditions":["Anorexia Nervosa"],"enrollment":50,"completionDate":"2026-08-30"},{"nctId":"NCT06613789","phase":"PHASE1","title":"Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But Uninfected","status":"NOT_YET_RECRUITING","sponsor":"HIV Vaccine Trials Network","startDate":"2026-07-13","conditions":["HIV Infections"],"enrollment":22,"completionDate":"2027-06-03"},{"nctId":"NCT02658253","phase":"PHASE1","title":"Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2016-01","conditions":["Malaria"],"enrollment":68,"completionDate":"2019-02-21"},{"nctId":"NCT07255976","phase":"PHASE4","title":"Comparison of Effectiveness of Gingival Displacement Using Retraction Cord and Aluminum Chloride Gel","status":"RECRUITING","sponsor":"Dow University of Health Sciences","startDate":"2024-09-11","conditions":["Gingival Bleeding","Prosthesis Failure, Dental","Tissue Injury"],"enrollment":66,"completionDate":"2025-12-30"},{"nctId":"NCT07059182","phase":"PHASE1","title":"Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Serum Life Science Europe GmbH","startDate":"2025-06-11","conditions":["PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE","Prevention of Pneumococcal-induced Acute Otitis Media"],"enrollment":30,"completionDate":"2025-08-29"},{"nctId":"NCT07119281","phase":"NA","title":"Gingival Retraction for Digital Scan Data","status":"COMPLETED","sponsor":"Istanbul University","startDate":"2024-02-01","conditions":["Data Accuracy, Bleeding Control"],"enrollment":50,"completionDate":"2025-05-04"},{"nctId":"NCT06799494","phase":"PHASE4","title":"HPV Vaccine Reduced Dose","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-08-06","conditions":["HPV"],"enrollment":100,"completionDate":"2028-09"},{"nctId":"NCT07122297","phase":"NA","title":"Evaluation of Gingival Displacement Methods","status":"COMPLETED","sponsor":"Zonguldak Bulent Ecevit University","startDate":"2015-12","conditions":["Gingival Displacement"],"enrollment":52,"completionDate":"2016-03"},{"nctId":"NCT04658667","phase":"PHASE1","title":"HIV Vaccine in HIV-uninfected Adults","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2022-02-03","conditions":["HIV"],"enrollment":81,"completionDate":"2024-07-01"},{"nctId":"NCT02952833","phase":"PHASE1","title":"ZIKA Vaccine in Naive Subjects","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-14","conditions":["Zika Virus Infection"],"enrollment":91,"completionDate":"2018-12-05"},{"nctId":"NCT07035054","phase":"PHASE2","title":"Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2024-04-20","conditions":["Streptococcus Pneumoniae Pneumonia"],"enrollment":992,"completionDate":"2024-11-30"},{"nctId":"NCT07025876","phase":"EARLY_PHASE1","title":"PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2023-11-18","conditions":["Streptococcus Pneumoniae Pneumonia"],"enrollment":240,"completionDate":"2024-07-30"},{"nctId":"NCT04314895","phase":"PHASE2","title":"Trial of NanoPac Intratumoral Injection in Lung Cancer","status":"COMPLETED","sponsor":"NanOlogy, LLC","startDate":"2021-04-14","conditions":["Lung Cancer, Nonsmall Cell","Lung Cancer","Lung Cancer, Small Cell","Neoplasm of Lung"],"enrollment":18,"completionDate":"2023-09-26"},{"nctId":"NCT04898283","phase":"PHASE3","title":"Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.","status":"RECRUITING","sponsor":"Inmunotek S.L.","startDate":"2021-05-31","conditions":["Rhinitis, Allergic","Rhinoconjunctivitis","Asthma, Allergic"],"enrollment":180,"completionDate":"2026-10"},{"nctId":"NCT04891237","phase":"PHASE3","title":"Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen","status":"RECRUITING","sponsor":"Inmunotek S.L.","startDate":"2021-06-14","conditions":["Rhinitis, Allergic","Rhinoconjunctivitis","Asthma, Allergic"],"enrollment":180,"completionDate":"2027-01"},{"nctId":"NCT06731374","phase":"PHASE4","title":"Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-02-24","conditions":["Pneumococcal Disease","Pneumococcal Carriage"],"enrollment":106,"completionDate":"2026-12"},{"nctId":"NCT05013983","phase":"PHASE1,PHASE2","title":"Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents","status":"WITHDRAWN","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2024-07","conditions":["COVID-19"],"enrollment":0,"completionDate":"2025-12"},{"nctId":"NCT04904471","phase":"PHASE3","title":"A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)","status":"COMPLETED","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2021-06-15","conditions":["COVID-19"],"enrollment":39663,"completionDate":"2023-11-01"},{"nctId":"NCT04826094","phase":"PHASE1","title":"A Study to Assess the Safety and Immune Response to Env-C DNA and Protein Vaccines in Kenya","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-03-15","conditions":["HIV Infections"],"enrollment":143,"completionDate":"2024-02-13"},{"nctId":"NCT05559983","phase":"PHASE1","title":"Dose Escalation Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2022-12-05","conditions":["Cholera Vaccination Reaction"],"enrollment":150,"completionDate":"2024-01-23"},{"nctId":"NCT04199689","phase":"PHASE3","title":"Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-27","conditions":["Papillomavirus Infections"],"enrollment":6033,"completionDate":"2028-08-31"},{"nctId":"NCT05359133","phase":"PHASE2","title":"A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain","status":"TERMINATED","sponsor":"Wex Pharmaceuticals Inc.","startDate":"2022-04-19","conditions":["Chemotherapy-induced Neuropathic Pain","Chemotherapy-induced Peripheral Neuropathy"],"enrollment":35,"completionDate":"2024-10-14"},{"nctId":"NCT06800131","phase":"PHASE1","title":"Hepatitis B Vaccine Delivered Trans-dermally by MAP","status":"NOT_YET_RECRUITING","sponsor":"International Vaccine Institute","startDate":"2025-02-05","conditions":["Hepatitis B Vaccine"],"enrollment":40,"completionDate":"2026-11-05"},{"nctId":"NCT06524947","phase":"PHASE3","title":"Clinical Trial of Protective Efficacy of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2024-07-27","conditions":["Acute Gastroenteropathy Due to Norovirus"],"enrollment":6600,"completionDate":"2027-03-28"},{"nctId":"NCT04066881","phase":"PHASE2","title":"A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP","status":"COMPLETED","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2020-12-15","conditions":["HIV Infections"],"enrollment":1512,"completionDate":"2024-12-31"},{"nctId":"NCT06678607","phase":"PHASE1","title":"Phase I Clinical Trial of PCV24 in People Aged 18 Years and Older","status":"COMPLETED","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2023-11-19","conditions":["Pneumococcal Infectious Disease"],"enrollment":240,"completionDate":"2024-07-28"},{"nctId":"NCT04722003","phase":"PHASE2","title":"Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-11-01","conditions":["Gonorrhoea"],"enrollment":52,"completionDate":"2023-10-02"},{"nctId":"NCT04563533","phase":"PHASE1,PHASE2","title":"Clinical Trial of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris)","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2020-08-05","conditions":["Acute Gastroenteritis"],"enrollment":580,"completionDate":"2024-09-29"},{"nctId":"NCT03284710","phase":"PHASE1,PHASE2","title":"Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-06-19","conditions":["HIV Infections"],"enrollment":132,"completionDate":"2019-12-12"},{"nctId":"NCT05934890","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13","status":"ACTIVE_NOT_RECRUITING","sponsor":"Walvax Biotechnology Co., Ltd.","startDate":"2023-11-23","conditions":["Pneumococcal Disease, Invasive"],"enrollment":630,"completionDate":"2026-02"},{"nctId":"NCT04582344","phase":"PHASE3","title":"Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)","status":"COMPLETED","sponsor":"Health Institutes of Turkey","startDate":"2020-09-14","conditions":["COVID-19"],"enrollment":10214,"completionDate":"2022-07-27"},{"nctId":"NCT04773665","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a","status":"COMPLETED","sponsor":"VBI Vaccines Inc.","startDate":"2021-03-15","conditions":["Covid19"],"enrollment":114,"completionDate":"2022-11-14"},{"nctId":"NCT04465539","phase":"NA","title":"The Potential Therapeutic Role of Hydroxyethyl Starch and Hydrocortisone in Acute Aluminum Phosphide Poisoning","status":"COMPLETED","sponsor":"Tanta University","startDate":"2020-07-15","conditions":["Potential Therapeutic Role"],"enrollment":60,"completionDate":"2024-03-30"},{"nctId":"NCT02963909","phase":"PHASE1","title":"A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-11-01","conditions":["Zika Virus Infection"],"enrollment":75,"completionDate":"2018-10-30"},{"nctId":"NCT06282692","phase":"PHASE3","title":"INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2023-06-19","conditions":["COVID-19 Pandemic","COVID-19 Vaccines"],"enrollment":400,"completionDate":"2024-07-19"},{"nctId":"NCT06272253","phase":"EARLY_PHASE1","title":"UNAIR Inactivated COVID-19 Vaccine INAVAC as Heterologue Booster (Immunobridging Study) in Adolescent Subjects","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2023-09-19","conditions":["COVID-19 Pandemic","COVID-19 Vaccines"],"enrollment":250,"completionDate":"2024-07-19"},{"nctId":"NCT06259578","phase":"EARLY_PHASE1","title":"UNAIR Inactivated COVID-19 Vaccine as Homologue Booster (Immunobridging Study)","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2024-01-29","conditions":["COVID-19 Pandemic","COVID-19 Vaccines","COVID-19 Virus Disease"],"enrollment":400,"completionDate":"2024-12-29"},{"nctId":"NCT05057169","phase":"PHASE4","title":"Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study)","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2021-11-18","conditions":["COVID-19 Vaccination"],"enrollment":400,"completionDate":"2025-12-31"},{"nctId":"NCT05949073","phase":"NA","title":"The Impact of Retraction Cords on the Gingival Margin Level.","status":"UNKNOWN","sponsor":"University of Jordan","startDate":"2023-07-25","conditions":["Gingival Retraction","Gingival Recession","Periodontal Health"],"enrollment":60,"completionDate":"2024-05-01"},{"nctId":"NCT05918939","phase":"EARLY_PHASE1","title":"UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study)","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2022-09-05","conditions":["COVID-19 Pandemic","COVID-19 Vaccines"],"enrollment":350,"completionDate":"2023-09-05"},{"nctId":"NCT05226429","phase":"PHASE1,PHASE2","title":"UNAIR Inactivated COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2022-02-08","conditions":["COVID-19 Pandemic","Vaccine Reaction"],"enrollment":495,"completionDate":"2023-07-06"},{"nctId":"NCT05876195","phase":"NA","title":"KLH Challenge to Explore the Human Immune Response","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2023-03-01","conditions":["Immune Response"],"enrollment":39,"completionDate":"2024-02"},{"nctId":"NCT03840174","phase":"PHASE1","title":"Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-03-08","conditions":["Cytomegalovirus Infections"],"enrollment":18,"completionDate":"2019-11-07"},{"nctId":"NCT05323435","phase":"PHASE2","title":"Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)","status":"COMPLETED","sponsor":"Jiangsu Rec-Biotechnology Co., Ltd.","startDate":"2022-05-30","conditions":["COVID-19"],"enrollment":300,"completionDate":"2023-01-16"},{"nctId":"NCT04644484","phase":"PHASE3","title":"A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety","status":"COMPLETED","sponsor":"Synermore Biologics (Suzhou) Co., Ltd.","startDate":"2020-09-23","conditions":["Rabies","Communicable Disease","Virus Diseases","Rhabdoviridae Infections","Mononegavirales Infections","RNA Virus Infections"],"enrollment":1000,"completionDate":"2022-12-16"},{"nctId":"NCT04998240","phase":"PHASE2","title":"Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2021-12-29","conditions":["Covid19"],"enrollment":360,"completionDate":"2024-02-28"},{"nctId":"NCT04742738","phase":"PHASE1,PHASE2","title":"Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19)","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2021-01-20","conditions":["COVID-19 (Healthy Volunteers)"],"enrollment":260,"completionDate":"2022-07-07"},{"nctId":"NCT05501444","phase":"NA","title":"Antiperspirant in the Treatment of Residual Limp Hyperhidrosis for Prosthetic Users","status":"COMPLETED","sponsor":"Sophies Minde Ortopedi","startDate":"2022-08-09","conditions":["Hyperhidrosis","Residual Limbs"],"enrollment":7,"completionDate":"2023-03-30"},{"nctId":"NCT04032093","phase":"PHASE2","title":"A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-08-07","conditions":["Respiratory Tract Infection"],"enrollment":1153,"completionDate":"2021-09-30"},{"nctId":"NCT03416348","phase":"PHASE1","title":"Hyperhidrosis, Developing a Treatment Approach Aims 1 & 2","status":"COMPLETED","sponsor":"University of Utah","startDate":"2018-05-08","conditions":["Hyperhidrosis"],"enrollment":95,"completionDate":"2022-02-14"},{"nctId":"NCT03236012","phase":"PHASE1","title":"Hyperhidrosis in Patients With Amputations-Botox","status":"COMPLETED","sponsor":"University of Utah","startDate":"2019-01-08","conditions":["Hyperhidrosis"],"enrollment":25,"completionDate":"2022-02-14"},{"nctId":"NCT05526820","phase":"PHASE4","title":"A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine","status":"COMPLETED","sponsor":"Sinovac (Dalian) Vaccine Technology Co., Ltd.","startDate":"2021-04-08","conditions":["Varicella"],"enrollment":450,"completionDate":"2022-02-27"},{"nctId":"NCT05508477","phase":"PHASE3","title":"UNAIR Inactivated COVID-19 Vaccine Phase III (Immunobridging Study)","status":"UNKNOWN","sponsor":"Dr. Soetomo General Hospital","startDate":"2022-06-28","conditions":["COVID-19 Pandemic","COVID-19 Vaccines"],"enrollment":4005,"completionDate":"2023-05-28"},{"nctId":"NCT05499351","phase":"PHASE4","title":"A Study of Booster Immunization With COVID-19 Vaccine,Inactivated Co -Administration With Influenza Vaccine and Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2021-10-15","conditions":["COVID-19"],"enrollment":3000,"completionDate":"2022-05-05"},{"nctId":"NCT04724655","phase":"EARLY_PHASE1","title":"Paraffin Oil or Coconut Oil in Acute Aluminum Phosphide Poisoning","status":"COMPLETED","sponsor":"Tanta University","startDate":"2021-01-01","conditions":["Aluminum Phosphide Poisoning"],"enrollment":89,"completionDate":"2021-09-15"},{"nctId":"NCT04780035","phase":"PHASE3","title":"Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19","status":"COMPLETED","sponsor":"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology \"Vector\"","startDate":"2020-11-27","conditions":["COVID-19"],"enrollment":3000,"completionDate":"2021-12-20"},{"nctId":"NCT04527575","phase":"PHASE1,PHASE2","title":"Study of the Safety, Reactogenicity and Immunogenicity of \"EpiVacCorona\" Vaccine for the Prevention of COVID-19","status":"COMPLETED","sponsor":"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology \"Vector\"","startDate":"2020-07-27","conditions":["Covid19"],"enrollment":100,"completionDate":"2021-12-30"},{"nctId":"NCT01927835","phase":"PHASE1","title":"Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South Africa","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT03382418","phase":"PHASE1","title":"Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-12-27","conditions":["HIV Infections"],"enrollment":45,"completionDate":"2019-09-25"},{"nctId":"NCT03827395","phase":"PHASE1","title":"Safety Study of Hepatitis E Vaccine (HEV239)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-12","conditions":["Hepatitis E","Immunisation"],"enrollment":25,"completionDate":"2020-08-28"},{"nctId":"NCT02669121","phase":"PHASE2","title":"Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-06-14","conditions":["Healthy Volunteers"],"enrollment":4748,"completionDate":"2018-06-16"},{"nctId":"NCT03433859","phase":"PHASE3","title":"Topical Aluminium Chloride vs OnabotulinumtoxinA Intradermal Injections in Residual Limb Hyperhidrosis (Lower Limbs)","status":"COMPLETED","sponsor":"Direction Centrale du Service de Santé des Armées","startDate":"2016-03","conditions":["Hyperhidrosis","Residual Limbs"],"enrollment":54,"completionDate":"2021-03-03"},{"nctId":"NCT04071158","phase":"PHASE2","title":"A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-10-01","conditions":["Respiratory Tract Infection"],"enrollment":713,"completionDate":"2019-12-11"},{"nctId":"NCT02531698","phase":"PHASE2","title":"A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-08","conditions":["MENINGOCOCCAL INFECTION"],"enrollment":400,"completionDate":"2017-03"},{"nctId":"NCT02028208","phase":"PHASE2","title":"Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study","status":"COMPLETED","sponsor":"Allerderm","startDate":"2013-11-04","conditions":["Contact Dermatitis"],"enrollment":56,"completionDate":"2016-05-24"},{"nctId":"NCT02661490","phase":"PHASE2","title":"Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-02-01","conditions":["Norovirus"],"enrollment":320,"completionDate":"2017-09-29"},{"nctId":"NCT02646891","phase":"PHASE1,PHASE2","title":"Safety and Immunogenicity Study of Trivalent P2-VP8 Subunit Rotavirus Vaccine in Adults, Toddlers and Infants","status":"COMPLETED","sponsor":"PATH","startDate":"2016-02-15","conditions":["Healthy"],"enrollment":618,"completionDate":"2017-12-22"},{"nctId":"NCT02472548","phase":"PHASE1","title":"A Study to Evaluate the Safety and Reactogenicity of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine","status":"COMPLETED","sponsor":"Dalhousie University","startDate":"2015-05","conditions":["Respiratory Syncytial Virus"],"enrollment":40,"completionDate":"2017-03-14"},{"nctId":"NCT02097472","phase":"PHASE1,PHASE2","title":"Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers","status":"COMPLETED","sponsor":"PATH","startDate":"2014-04","conditions":["Pneumonia, Pneumococcal"],"enrollment":304,"completionDate":"2015-12"},{"nctId":"NCT01717950","phase":"PHASE1","title":"Safety and Immunogenicity of the Na-APR-1 Hookworm Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2013-09","conditions":["Hookworm Infection","Hookworm Disease"],"enrollment":40,"completionDate":"2015-09"},{"nctId":"NCT02109354","phase":"PHASE1","title":"Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"HIV Vaccine Trials Network","startDate":"2013-06-18","conditions":["HIV Infection"],"enrollment":202,"completionDate":"2015-02-02"},{"nctId":"NCT02612909","phase":"PHASE2,PHASE3","title":"A Safety and Immunogenicity Study of IVACFLU-A/H5N1","status":"COMPLETED","sponsor":"Institute of Vaccines and Medical Biologicals, Vietnam","startDate":"2017-03-07","conditions":["Avian Influenza"],"enrollment":930,"completionDate":"2017-08-30"},{"nctId":"NCT01764256","phase":"PHASE1","title":"A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2012-12","conditions":["Rotavirus Infection"],"enrollment":48,"completionDate":"2013-09"},{"nctId":"NCT01168401","phase":"PHASE1","title":"Bivalent Norovirus Vaccine Study","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-09-03","conditions":["Gastroenteritis"],"enrollment":102,"completionDate":"2013-01-09"},{"nctId":"NCT02116998","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae","status":"COMPLETED","sponsor":"Genocea Biosciences, Inc.","startDate":"2014-09","conditions":["Pneumococcal Infections","Pneumonia, Pneumococcal"],"enrollment":98,"completionDate":"2016-04"},{"nctId":"NCT02277184","phase":"PHASE1","title":"Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Julie E. Bauman, MD, MPH","startDate":"2015-09","conditions":["Carcinoma, Squamous Cell of Head and Neck"],"enrollment":1,"completionDate":"2016-09"},{"nctId":"NCT03250533","phase":"NA","title":"Analysis of the Effects of LED Phototherapy and Electrical Stimulation in the Healing of Diabetic Ulcers","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2017-09-01","conditions":["Ulcer","Diabetes Mellitus"],"enrollment":52,"completionDate":"2021-06-30"},{"nctId":"NCT02142504","phase":"PHASE2","title":"Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-05-15","conditions":["Norovirus Prevention"],"enrollment":454,"completionDate":"2016-01-06"},{"nctId":"NCT01459393","phase":"PHASE3","title":"Comparison Between 5-aminolevulinic Acid Photodynamic Therapy Versus Cryotherapy for Actinic Keratosis Treatment","status":"COMPLETED","sponsor":"Barretos Cancer Hospital","startDate":"2010-11","conditions":["Actinic Keratosis"],"enrollment":137,"completionDate":"2011-11"},{"nctId":"NCT00220740","phase":"PHASE3","title":"Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2004-04","conditions":["Polyradiculoneuropathy, Chronic Inflammatory Demyelinating"],"enrollment":117,"completionDate":"2006-06"},{"nctId":"NCT01096134","phase":"NA","title":"Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention","status":"COMPLETED","sponsor":"Jhpiego","startDate":"2011-01","conditions":["Cervical Cancer"],"enrollment":8000,"completionDate":"2012-11"},{"nctId":"NCT01799954","phase":"PHASE1","title":"Evaluating the Safety and Priming Response of an HIV Vaccine Regimen in Healthy, HIV-Uninfected Adults","status":"COMPLETED","sponsor":"HIV Vaccine Trials Network","startDate":"2012-08","conditions":["HIV Infections"],"enrollment":96,"completionDate":"2014-12"},{"nctId":"NCT00509886","phase":"NA","title":"Non-prescription Versus Prescription Topical Treatments Versus no Treatment in the Control of Sweating","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2007-06","conditions":["Hyperhidrosis","Excess Sweating"],"enrollment":24,"completionDate":"2007-08"},{"nctId":"NCT01827397","phase":"PHASE1","title":"Safety & Immunogenicity of Immunisations With EN41-UGR7C HIV Vaccine","status":"COMPLETED","sponsor":"PX'Therapeutics","startDate":"2013-04","conditions":["- HIV"],"enrollment":24,"completionDate":"2014-02"},{"nctId":"NCT01986335","phase":"PHASE3","title":"Protectivity and Safety of DTP/HB/Hib (Bio Farma) Vaccines in Infants, Batch Consistency, Multi Center Trial","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2012-08","conditions":["Healthy"],"enrollment":600,"completionDate":"2013-01"},{"nctId":"NCT01986322","phase":"PHASE2","title":"Immunogenicity and Safety of DTP/HB/Hib (Bio Farma)Compared to DTP/HB Given Simultaneously With Hib(Registered)Vaccine","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2011-07","conditions":["Healthy"],"enrollment":220,"completionDate":"2012-01"},{"nctId":"NCT01977196","phase":"PHASE1","title":"The Safety and Immunogenicity of DTP/Hepatitis B 10ug Hib Vaccine (Bio Farma)","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2011-04","conditions":["Healthy"],"enrollment":30,"completionDate":"2011-07"},{"nctId":"NCT01281501","phase":"PHASE4","title":"Symptomatic Relief of Acute Dyspeptic Pain in Emergency Department With Pantoprazole","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2011-01","conditions":["Dyspepsia","Emergency","Pain"],"enrollment":87,"completionDate":"2011-10"},{"nctId":"NCT00347555","phase":"PHASE1","title":"Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-05","conditions":["Plasmodium Falciparum Malaria"],"enrollment":80,"completionDate":"2008-04"},{"nctId":"NCT01026246","phase":"PHASE1","title":"EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-immune Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-06","conditions":["Plasmodium Falciparum Malaria"],"enrollment":60,"completionDate":"2012-03"},{"nctId":"NCT01273233","phase":"PHASE1","title":"Safety of an Inactivated Enterovirus Type 71 Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2010-12","conditions":["Infection; Viral, Enterovirus"],"enrollment":36,"completionDate":"2011-02"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Topical","formulation":"Cloth, Cream, Gel, Liquid","formulations":[{"form":"CLOTH","route":"TOPICAL","productName":"Antiperspirant Towlette"},{"form":"CREAM","route":"TOPICAL","productName":"Hand Antiperspirant Nightly Use"},{"form":"GEL","route":"TOPICAL","productName":"DURADRY PM"},{"form":"LIQUID","route":"TOPICAL","productName":"Aarica"},{"form":"LIQUID","route":"TOPICAL","productName":"CERTAIN DRIROLL-ON"},{"form":"LIQUID","route":"TOPICAL","productName":"Clinical Strength MiracleDry Antiperspirant Deodorant  PM"},{"form":"LIQUID","route":"TOPICAL","productName":"Dr Sweat"},{"form":"LIQUID","route":"TOPICAL","productName":"PURAX"},{"form":"LIQUID","route":"TOPICAL","productName":"Xerac AC"},{"form":"LIQUID","route":"TOPICAL","productName":"Zero Sweat"},{"form":"LIQUID","route":"TOPICAL","productName":"ZeroSweat with Aloe"},{"form":"LIQUID","route":"TOPICAL","productName":"ZeroSweat3 DAY PROTECTION ANTIPERSPIRANT"},{"form":"SOLUTION","route":"DENTAL","productName":"Gingi-Aid Solution"},{"form":"SOLUTION","route":"DENTAL","productName":"Frenna AC"},{"form":"SOLUTION","route":"DENTAL","productName":"Gibson Healthcare Buffered Hemostatic Solution"}]},"crossReferences":{"NUI":"N0000147141","MMSL":"34846","NDDF":"001934","UNII":"3CYT62D3GA","VUID":"4018839","VANDF":"4018839","RXNORM":"46241","UMLSCUI":"C0102840","chemblId":"CHEMBL4594252","ChEMBL_ID":"CHEMBL3833401","KEGG_DRUG":"D02845","DRUGBANK_ID":"DB11081","PUBCHEM_CID":"24012","SNOMEDCT_US":"387372003","SECONDARY_CAS_RN":"7784-13-6","MESH_DESCRIPTOR_UI":"D000077410"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":628,"therapeuticAreas":["Dermatology"],"atcClassification":{"source":"DrugCentral","atcCode":"D10AX01","allCodes":["D10AX01"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 16","pmid":"41901430","title":"Spectrophotometric Estimation of Polyphenolic Compounds in Willowherbs (Epilobium angustifolium L. and E. hirsutum L.) and Implications for Genetic Resource Conservation.","journal":"Plants (Basel, Switzerland)"},{"date":"2026 Mar","pmid":"41883085","title":"Morinda lucida Leaf Metabolites Ameliorate Aluminium Chloride-Mediated Chronic Inflammation and Modulate Proteins-Linked to Erectile Dysfunction in Rat Testes.","journal":"Chemistry & biodiversity"},{"date":"2026 Apr","pmid":"41808725","title":"Neuroprotective potential of silver nanoparticles synthesized using Sargassum polycystum in a Zebrafish model of Alzheimer's disease.","journal":"3 Biotech"},{"date":"2026 Jun","pmid":"41732170","title":"Neuroprotective properties of Linzia gerberiformis aqueous leaves extract against aluminium chloride (AlCl(3)) -induced cognitive impairment: Involvement of cholinergic, GABAergic, and antioxidant mechanisms.","journal":"IBRO neuroscience reports"},{"date":"2026 Mar","pmid":"41651776","title":"Phytochemical Screening and Antioxidant Capacity of Chloroxylon swietenia DC. Leaf Extracts.","journal":"Biomedical chromatography : BMC"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:01:30.389811+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}